PYCR3

Summary

PYCR3 (pyrroline-5-carboxylate reductase 3, HGNC:25846) is a protein-coding gene on chromosome 8q24.3, encoding Pyrroline-5-carboxylate reductase 3 (Q53H96). Oxidoreductase that catalyzes the last step in proline biosynthesis, which corresponds to the reduction of pyrroline-5-carboxylate (P5C) to L-proline using NAD(P)H.

This gene encodes a protein that belongs to the pyrroline-5-carboxylate reductase family of enzymes. Members of this family catalyze the final step in proline biosynthesis, converting pyrroline-5-carboxylate to proline. Glutamate and ornithine are precursors in the synthesis of proline. The protein encoded by this gene is a cytoplasmic enzyme involved in the biosynthesis of proline from ornithine.

Source: NCBI Gene 65263 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_023078

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25846
Approved symbol	PYCR3
Name	pyrroline-5-carboxylate reductase 3
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13852
Ensembl gene	ENSG00000104524
Ensembl biotype	protein_coding
OMIM	616408
Entrez	65263

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000377579, ENST00000433751, ENST00000447926, ENST00000462036, ENST00000482616, ENST00000495276, ENST00000863892, ENST00000928173, ENST00000957034

RefSeq mRNA: 2 — MANE Select: NM_023078 NM_001329866, NM_023078

CCDS: CCDS6407, CCDS94351

Canonical transcript exons

ENST00000495276 — 6 exons

Exon	Start	End
ENSE00003541865	143606062	143606154
ENSE00003595007	143608062	143608126
ENSE00003628708	143603210	143605882
ENSE00003673519	143606953	143607132
ENSE00003731451	143606467	143606679
ENSE00003744680	143609458	143609575

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 82.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.3216 / max 104.2428, expressed in 1707 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95506	12.2072	1706
95504	0.1144	54

Top tissues by expression

139 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prefrontal cortex	UBERON:0000451	82.79	gold quality
anterior cingulate cortex	UBERON:0009835	82.06	gold quality
frontal cortex	UBERON:0001870	81.88	gold quality
right lobe of liver	UBERON:0001114	81.10	gold quality
right frontal lobe	UBERON:0002810	81.09	gold quality
cerebral cortex	UBERON:0000956	80.97	gold quality
Ammon’s horn	UBERON:0001954	80.71	gold quality
temporal lobe	UBERON:0001871	80.48	gold quality
amygdala	UBERON:0001876	80.32	gold quality
right uterine tube	UBERON:0001302	80.23	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.11	gold quality
mucosa of transverse colon	UBERON:0004991	79.82	gold quality
telencephalon	UBERON:0001893	79.73	gold quality
Brodmann (1909) area 9	UBERON:0013540	79.30	gold quality
nucleus accumbens	UBERON:0001882	78.97	gold quality
adenohypophysis	UBERON:0002196	78.86	gold quality
pituitary gland	UBERON:0000007	78.69	gold quality
right adrenal gland	UBERON:0001233	78.41	gold quality
superior frontal gyrus	UBERON:0002661	78.20	gold quality
left adrenal gland	UBERON:0001234	78.15	gold quality
left adrenal gland cortex	UBERON:0035825	78.07	gold quality
right lobe of thyroid gland	UBERON:0001119	78.03	gold quality
putamen	UBERON:0001874	78.02	gold quality
brain	UBERON:0000955	77.99	gold quality
right adrenal gland cortex	UBERON:0035827	77.67	gold quality
caudate nucleus	UBERON:0001873	77.66	gold quality
hypothalamus	UBERON:0001898	77.18	gold quality
adult mammalian kidney	UBERON:0000082	77.11	gold quality
left lobe of thyroid gland	UBERON:0001120	76.93	gold quality
liver	UBERON:0002107	76.90	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.88

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting PYCR3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-6848-3P	99.64	66.49	885
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4441	99.49	66.56	3216

Literature-anchored findings (GeneRIF, showing 1)

• PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer. (PMID:38642827)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	pycr3	ENSDARG00000015236
mus_musculus	Pycr3	ENSMUSG00000022571

Paralogs (3): PYCR2 (ENSG00000143811), NOXRED1 (ENSG00000165555), PYCR1 (ENSG00000183010)

Protein

Protein identifiers

Pyrroline-5-carboxylate reductase 3 — Q53H96 (reviewed: Q53H96)

Alternative names: Pyrroline-5-carboxylate reductase-like protein

All UniProt accessions (4): A0A087WTU2, B5MD87, Q53H96, F8WEI0

UniProt curated annotations — full annotation on UniProt →

Function. Oxidoreductase that catalyzes the last step in proline biosynthesis, which corresponds to the reduction of pyrroline-5-carboxylate (P5C) to L-proline using NAD(P)H. Proline is synthesized from either glutamate or ornithine; both are converted to P5C, and then to proline via pyrroline-5-carboxylate reductases (PYCRs). PYCR3 is exclusively linked to the biosynthesis of proline from ornithine.

Subunit / interactions. Homodecamer; composed of 5 homodimers.

Subcellular location. Cytoplasm.

Activity regulation. Competitive inhibition by proline analog N-formyl-L-proline. Weakly inhibited by proline.

Pathway. Amino-acid biosynthesis; L-proline biosynthesis; L-proline from L-glutamate 5-semialdehyde: step 1/1.

Similarity. Belongs to the pyrroline-5-carboxylate reductase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53H96-1	1	yes
Q53H96-2	2

RefSeq proteins (2): NP_001316795, NP_075566* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000304	Pyrroline-COOH_reductase	Family
IPR008927	6-PGluconate_DH-like_C_sf	Homologous_superfamily
IPR028939	P5C_Rdtase_cat_N	Domain
IPR029036	P5CR_dimer	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR053790	P5CR-like_CS	Conserved_site

Pfam: PF03807, PF14748

Catalyzed reactions (Rhea), 2 shown:

• L-proline + NAD(+) = (S)-1-pyrroline-5-carboxylate + NADH + 2 H(+) (RHEA:14105)
• L-proline + NADP(+) = (S)-1-pyrroline-5-carboxylate + NADPH + 2 H(+) (RHEA:14109)

UniProt features (7 total): sequence variant 3, initiator methionine 1, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53H96-F1	94.84	0.93

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8964539	Glutamate and glutamine metabolism

MSigDB gene sets: 114 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, ELVIDGE_HYPOXIA_DN, GOBP_GLUTAMINE_FAMILY_AMINO_ACID_BIOSYNTHETIC_PROCESS, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, MODULE_255, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, MODULE_317, GOBP_AMINO_ACID_BIOSYNTHETIC_PROCESS, GOBP_GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, SMID_BREAST_CANCER_LUMINAL_B_UP, LIAO_METASTASIS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, FISCHER_DREAM_TARGETS

GO Biological Process (3): L-proline biosynthetic process (GO:0055129), obsolete proline biosynthetic process (GO:0006561), amino acid biosynthetic process (GO:0008652)

GO Molecular Function (4): pyrroline-5-carboxylate reductase activity (GO:0004735), identical protein binding (GO:0042802), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): cytosol (GO:0005829), intercellular bridge (GO:0045171), mitotic spindle (GO:0072686), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of amino acids and derivatives	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
L-proline metabolic process	1
glutamate family amino acid biosynthetic process	1
amino acid metabolic process	1
biosynthetic process	1
oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor	1
protein binding	1
binding	1
catalytic activity	1
cytoplasm	1
spindle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1134 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PYCR3	ALDH18A1	P54886	775
PYCR3	PRODH	O43272	692
PYCR3	OAT	P04181	679
PYCR3	ALDH4A1	P30038	674
PYCR3	PRODH	O43272	661
PYCR3	TIGD5	Q53EQ6	608
PYCR3	COMMD5	Q9GZQ3	559
PYCR3	L3HYPDH	Q96EM0	528
PYCR3	ASS1	P00966	497
PYCR3	OSBPL7	Q9BZF2	459
PYCR3	NRBP2	Q9NSY0	459
PYCR3	NOXRED1	Q6NXP6	450
PYCR3	MRPL55	Q7Z7F7	447
PYCR3	POP1	Q99575	447
PYCR3	PSPH	P78330	422

IntAct

71 interactions, top by confidence:

A	B	Type	Score
SDCBP	PYCR3	psi-mi:“MI:0915”(physical association)	0.720
PYCR3	SDCBP	psi-mi:“MI:0915”(physical association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PYCR3	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
BAG4	PYCR3	psi-mi:“MI:0915”(physical association)	0.560
PSMB1	PYCR3	psi-mi:“MI:0915”(physical association)	0.560
CDKN2B	PYCR3	psi-mi:“MI:0915”(physical association)	0.560
KSR2	POLR3A	psi-mi:“MI:0914”(association)	0.530
PYCR1	PYCR3	psi-mi:“MI:0914”(association)	0.530
MRPS18C	MRPS14	psi-mi:“MI:0914”(association)	0.530
PYCR3	RPL23	psi-mi:“MI:0914”(association)	0.530
KCNG1	PYCR3	psi-mi:“MI:0915”(physical association)	0.400
PYCR3	PYCR3	psi-mi:“MI:0915”(physical association)	0.370
PYCR3	FXR1	psi-mi:“MI:0915”(physical association)	0.370
PYCR3	FXR2	psi-mi:“MI:0915”(physical association)	0.370
PYCR3	HOXA1	psi-mi:“MI:0915”(physical association)	0.370
LBP	PYCR3	psi-mi:“MI:0915”(physical association)	0.370
PYCR3	PRMT6	psi-mi:“MI:0915”(physical association)	0.370
Tp53bp1	WBP2	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
TBC1D22B	MAD2L1	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
PCMT1	YDJC	psi-mi:“MI:0914”(association)	0.350
PYCR2	MYO1F	psi-mi:“MI:0914”(association)	0.350
ENG	IGKV2-28	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
	DENND11	psi-mi:“MI:0914”(association)	0.350

BioGRID (137): PYCRL (Affinity Capture-MS), PYCRL (Two-hybrid), PYCRL (Two-hybrid), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), GPD1L (Co-fractionation), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Affinity Capture-MS), PYCRL (Two-hybrid), PYCRL (Affinity Capture-MS)

ESM2 similar proteins: A0KF08, A1L2Q8, A4ST20, A4W537, A8ARJ5, B0TLE9, B1KQ10, B4RQK9, B7GU03, B8J2B6, C1F6U2, E9AD19, O04016, O48881, P0A9L8, P0A9L9, P0C1E4, P0C1E5, P17817, P32263, P32322, P54904, P74572, Q04708, Q0QLF5, Q0SYD4, Q17QJ7, Q1DCL2, Q1GZ87, Q20848, Q3IIE0, Q4R531, Q4R6W7, Q53H96, Q58D08, Q58DT4, Q5PQJ6, Q5QZB8, Q5R9X6, Q5RAQ3

Diamond homologs: A0A348AXY1, A0A411KUQ8, A1L2Q8, E0TY11, O04016, P0CI77, P17817, P54552, P54893, P54904, P74572, Q04708, Q12641, Q12740, Q20848, Q4R531, Q53H96, Q58D08, Q5PQJ6, Q5RAQ3, Q5SPD7, Q96C36, Q9DCC4, Q9HH99, Q9P7Y7, P0A9L8, P0A9L9, P0C1E4, P0C1E5, P22008, P27771, P32263, P32322, P46725, P52053, P9WHU6, P9WHU7, Q17QJ7, Q4R6W7, Q58DT4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1300 predictions. Top by Δscore:

Variant	Effect	Δscore
8:143605702:A:AC	donor_gain	1.0000
8:143605703:C:CC	donor_gain	1.0000
8:143606162:C:CT	acceptor_gain	1.0000
8:143606165:G:T	acceptor_gain	1.0000
8:143606459:ATACT:A	donor_loss	1.0000
8:143606463:TCACG:T	donor_loss	1.0000
8:143606464:CA:C	donor_loss	1.0000
8:143606465:A:AC	donor_gain	1.0000
8:143606465:AC:A	donor_loss	1.0000
8:143606466:C:CG	donor_gain	1.0000
8:143606466:CG:C	donor_gain	1.0000
8:143606466:CGA:C	donor_gain	1.0000
8:143606466:CGAA:C	donor_gain	1.0000
8:143606685:C:CT	acceptor_gain	1.0000
8:143606948:CTCA:C	donor_loss	1.0000
8:143606949:TCAC:T	donor_loss	1.0000
8:143606950:CAC:C	donor_loss	1.0000
8:143606951:A:AC	donor_gain	1.0000
8:143606951:A:AT	donor_loss	1.0000
8:143606951:ACCT:A	donor_gain	1.0000
8:143606952:C:CC	donor_gain	1.0000
8:143606952:CCT:C	donor_gain	1.0000
8:143606952:CCTC:C	donor_gain	1.0000
8:143608060:A:AC	donor_gain	1.0000
8:143608061:C:CC	donor_gain	1.0000
8:143608075:AGGTT:A	donor_gain	1.0000
8:143608079:T:TA	donor_gain	1.0000
8:143605703:CTTT:C	donor_gain	0.9900
8:143605880:CCC:C	acceptor_gain	0.9900
8:143605881:CC:C	acceptor_gain	0.9900

AlphaMissense

1743 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:143606638:G:C	N126K	0.983
8:143606638:G:T	N126K	0.983
8:143608095:A:C	S41R	0.980
8:143608095:A:T	S41R	0.980
8:143608097:T:G	S41R	0.980
8:143606485:A:C	S177R	0.977
8:143606485:A:T	S177R	0.977
8:143606487:T:G	S177R	0.977
8:143609511:A:G	F13S	0.975
8:143606467:G:C	F183L	0.974
8:143606467:G:T	F183L	0.974
8:143606469:A:G	F183L	0.974
8:143606479:A:C	S179R	0.974
8:143606479:A:T	S179R	0.974
8:143606481:T:G	S179R	0.974
8:143606631:A:G	C129R	0.973
8:143606616:C:A	G134W	0.970
8:143605876:C:G	A217P	0.969
8:143609510:G:C	F13L	0.969
8:143609510:G:T	F13L	0.969
8:143609512:A:G	F13L	0.969
8:143605875:G:T	A217D	0.968
8:143608099:G:T	A40D	0.968
8:143609505:C:T	G15D	0.968
8:143605747:C:G	A260P	0.965
8:143607123:A:G	C56R	0.964
8:143605746:G:T	A260D	0.963
8:143608105:A:T	I38K	0.963
8:143605791:A:G	L245P	0.959
8:143606090:G:T	A205D	0.958

dbSNP variants (sampled 300 via entrez): RS1001161514 (8:143607879 C>T), RS1001480199 (8:143609695 C>A,T), RS1001884430 (8:143602770 C>A,G,T), RS1001931431 (8:143607745 G>A,C), RS1002284891 (8:143604774 C>T), RS1002498650 (8:143611267 G>A), RS1003092965 (8:143610415 C>A,T), RS1003296117 (8:143606321 C>T), RS1003569404 (8:143602773 C>T), RS1003957624 (8:143608163 G>T), RS1004161478 (8:143603489 G>GTGGC), RS1004517533 (8:143603439 G>A), RS1004733080 (8:143603698 A>T), RS1005422711 (8:143610950 G>A), RS1006426829 (8:143604514 C>G,T)

Disease associations

OMIM: gene MIM:616408 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001966_2	Rhegmatogenous retinal detachment	3.000000e-06
GCST004621_125	Red cell distribution width	1.000000e-11
GCST008459_52	Schizophrenia	4.000000e-08
GCST008459_53	Schizophrenia	1.000000e-09
GCST012020_17	Serum metabolite levels	5.000000e-144
GCST90002391_195	Mean corpuscular hemoglobin concentration	6.000000e-09
GCST90002404_104	Red cell distribution width	7.000000e-40

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009188	Red cell distribution width
EFO:0004528	mean corpuscular hemoglobin concentration

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, affects expression, decreases expression	4
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	affects cotreatment, increases expression, increases methylation	2
aristolochic acid I	decreases expression	1
Esketamine	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
ICG 001	decreases expression	1
abrine	decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases response to substance, decreases expression	1
NSC 689534	decreases expression, affects binding	1
Sunitinib	decreases expression	1
Arsenic	increases abundance, affects cotreatment, decreases expression	1
Copper	decreases expression, affects binding	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Manganese	increases abundance, affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9Q7	Ubigene HEK293 PYCR3 KO	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer